Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • 15 hours ago

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • 13 hours ago

Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs

Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.

Zacks Investment Research • 10 hours ago

Should You Continue to Hold ILMN Stock in Your Portfolio?

Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.

Zacks Investment Research • Jul 3, 2026

AZN vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Jul 1, 2026

Here's Why Illumina (ILMN) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 29, 2026

Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip

Swiss pharma and diagnostics giant Roche on Monday launched its ​long-awaited Axelios gene sequencer, in a bid to challenge ‌U.S. firm Illumina's leadership in next-generation sequencing.

Reuters • Jun 29, 2026

Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.

PRNewsWire • Jun 23, 2026

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 17, 2026

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Forbes • Jun 17, 2026